Evaluating TAB2, IKBKB, and IKBKG Gene Polymorphisms and Serum Protein Levels and Their Association with Age-Related Macular Degeneration and Its Treatment Efficiency
Alvita Vilkeviciute, Enrika Pileckaite, Akvile Bruzaite, Dzastina Cebatoriene, Greta Gedvilaite-Vaicechauskiene, Loresa Kriauciuniene, Dalia Zaliuniene, Rasa Liutkeviciene · 2024
Read Evaluating TAB2, IKBKB, and IKBKG Gene Polymorphisms and Serum Protein Levels and Their Association with Age-Related Macular Degeneration and Its Treatment Efficiency by Alvita Vilkeviciute, Enrika Pileckaite, Akvile Bruzaite, Dzastina Cebatoriene, Greta Gedvilaite-Vaicechauskiene, Loresa Kriauciuniene, Dalia Zaliuniene, Rasa Liutkeviciene (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11677027.txt.
Description
Alvita Vilkeviciute and co-authors test three inflammation-pathway genes for links to age-related macular degeneration, in this 2024 Europe PMC paper. The disease is a leading cause of blindness, killing the retina's support layer and then its light sensors. Nearly a thousand people, healthy controls and patients with early or advanced wet disease, were genotyped, and blood protein levels were measured.
One variant in the TAB2 gene emerged as a risk factor for both early and advanced disease. Among wet-disease patients, the same pattern held in women but not men, hinting at sex-specific pathways. Patients were also split by whether anti-VEGF injections worked, connecting the genetics to treatment response.
Catalog record
| CREATOR | Alvita Vilkeviciute, Enrika Pileckaite, Akvile Bruzaite, Dzastina Cebatoriene, Greta Gedvilaite-Vaicechauskiene, Loresa Kriauciuniene, Dalia Zaliuniene, Rasa Liutkeviciene |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |